Dietary Supplements Vit D, Quercetin and Curcumin Combination for Early Symptoms of COVID-19

• Status: Recruiting
• Trial end date: 2021-12-31
• Target enrollment: 0
• Participant gender: All

Summary

There is currently no specific treatment available for COVID-19 disease. There is an urgent need for affordable, worldwide available and safe agents for treatment of COVID-19. Dietary supplements Curcumin, Quercetin and Vitamin D are widely used to boost the body's immune system against infections. In the present study, the combination of dietary supplements curcumin, quercetin and vitamin D, all contained in one soft capsule (Nasafytol), will be investigated for early COVID-19 symptoms improvement and viral clearance in outpatients.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Ayub Teaching Hospital
• Treatments: Curcumin; Quercetin; Vitamin D

Criteria

Inclusion Criteria:

• Patients must be 18 years of age or older, of either gender

• Patients must be tested positive for SARS-CoV-2 by RT-PCR

• Patients must exhibit typical symptoms of COVID-19 disease at screening such as fever, fatigue, a dry and contagious cough, loss of appetite, body aches, shortness of breath, mucus or phlegm, sore throat, headache, chills, sometimes withshaking, loss of smell or taste, congestion or runny nose, nausea, or vomiting, diarrhea, muscular pain etc.

• Patients must be in the early stage of COVID-19 disease who do not require hospitalization at the time of screening

• Patients must be under the care of a Physician for diagnosis of COVID-19

• Patients who have signed informed consent

Exclusion Criteria:

• Patients with proven hypersensitivity or allergic reaction to quercetin or curcumin

• Patients with known chronic kidney disease with estimated creatinine clearance < 50 mL/minute or need for dialysis

• Patients who are severely hypotensive defined as needing hemodynamic pressors to maintain blood pressure

• Patients taking anticoagulant/antiplatelet drugs such as Coumarine, Heparine, Aspirin, Clopidrogel, dalteparin, enoxaparin, ticlopidine and warparin.

• Patients with gallstone obstruction

• Hypothyroid suppering patients

• Patients with moderate or severe thrombocytopenia (platelet count <100 ×10⁹/L);

• Pregnant patients